// App-Quantinova.ai

: Co-expression of PD-L1 and oncogenic receptor tyrosine kinases HER2 and cMET is low in metastatic urothelial carcinoma.

Researchers

Presenter

  • Justin T. Matulay

Principal Investigators

  • Chad A. Livasy

  • James Thomas Symanowski

  • Claud Grigg

  • Nathanael C. Haynes

  • Peter E Clark

  • Derek Raghavan

  • Earle F Burgess

Medical Centers

  • Levine Cancer Institute, Atrium Health, Charlotte, NC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • Programmed death-ligand 1

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved